Cullinan Oncology
CGEM
75 hedge funds and large institutions have $559M invested in Cullinan Oncology in 2021 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 29 increasing their positions, 16 reducing their positions, and 8 closing their positions.
113% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 8
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
81% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 16
14% more funds holding
Funds holding: 66 → 75 (+9)
5.51% more ownership
Funds ownership: 77.77% → 83.28% (+5.5%)
0% more call options, than puts
Call options by funds: $1K | Put options by funds: $1K
27% less capital invested
Capital invested by funds: $762M → $559M (-$203M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$92.4M |
| 2 |
State Street
Boston,
Massachusetts
|
+$16.2M |
| 3 |
Morgan Stanley
New York
|
+$5.16M |
| 4 |
CA
CHI Advisors
New York
|
+$4.63M |
| 5 |
BlackRock
New York
|
+$4.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMV
Foresite Capital Management V
Larkspur,
California
|
-$31.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$31.1M |
| 3 |
VA
VR Adviser
New York
|
-$15.9M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$8.57M |
| 5 |
DM
Deerfield Management
New York
|
-$7.43M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Millennium Management
New York
| – | -$4.67M | -207,030 | Closed |
|
|
PVI
77
Pura Vida Investments
New York
| – | -$1.84M | -81,418 | Closed |
|
|
SSA
78
Schonfeld Strategic Advisors
New York
| – | -$809K | -35,858 | Closed |
|
|
MFS
79
Mirabella Financial Services
London,
United Kingdom
| – | -$670K | -29,686 | Closed |
|
|
B
80
Bailard
Foster City,
California
| – | -$217K | -9,600 | Closed |
|
81
VOYA Investment Management
Atlanta,
Georgia
| – | -$215K | -9,518 | Closed |
|
|
SO
82
STRS Ohio
Columbus,
Ohio
| – | -$83K | -3,700 | Closed |
|
CGEM Hedge Fund Activity: Q4 2021 in Review
75 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Cullinan Oncology (CGEM) for Q4 2021, worth a combined $559M — down 27% from $762M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new CGEM positions and 8 closed out — a net gain of 9 holders — while 29 added to existing stakes and 16 trimmed.
The largest buyer was BVF Inc, adding an estimated $92.4M. The largest seller was Foresite Capital Management V, cutting an estimated $31.7M.
- 75 institutional investors held Cullinan Oncology (CGEM) as of Q4 2021, up from 66 in Q3 2021.
- Funds reported $559M of Cullinan Oncology stock for Q4 2021, down 27% quarter-over-quarter.
- 17 funds opened new Cullinan Oncology positions in Q4 2021 and 8 closed out, a net change of +9 holders.
- The largest Cullinan Oncology buyer in Q4 2021 was BVF Inc, an estimated $92.4M added.
- The largest Cullinan Oncology seller in Q4 2021 was Foresite Capital Management V, an estimated $31.7M sold.
Based on aggregated 13F filings for Q4 2021.